Contact Us
Library Background

Patents

We have been involved in a large number of highly successful drug discovery projects with our collaborators and partners.

Listed here are U.S. composition of matter patents emerging from these collaborations on which our scientists are inventors. To view additional patent information, please visit the U.S. Patent and Trademark Office website.

Year Title Patent Number Assignee
2022 TYK2 inhibitors and uses thereof 11220508 Nimbus Therapeutics
2022 TYK2 inhibitors and uses thereof 11434240 Nimbus Therapeutics
2022 Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors 11414431 Nimbus Therapeutics
2021 Therapeutic compounds and compositions 10988448 Agios
2021 Inhibiting αvβ6 integrin 11021480 Morphic Therapeutic
2021 Inhibitors of αvβ6 integrin 11040955 Morphic Therapeutic
2021 Inhibitors of αvβ6 integrin 11046669 Morphic Therapeutic
2021 Inhibitors of αvβ6 integrin 11046685 Morphic Therapeutic
2021 Inhibiting human integrin α4β7 11104661 Morphic Therapeutic
2021 Antagonists of human integrin α4β7 11174228 Morphic Therapeutic
2021 Pyrazole ACC inhibitors and uses thereof 10941158 Nimbus Therapeutics
2021 Ester ACC inhibitors and uses thereof 11098055 Nimbus Therapeutics
2021 TYK2 inhibitors and uses thereof 10968236 Nimbus Therapeutics
2021 TYK2 inhibitors, uses, and methods for production thereof 11040967 Nimbus Therapeutics
2021 TYK2 inhibitors and uses thereof 11046698 Nimbus Therapeutics
2021 TYK2 inhibitors and uses thereof 11053241 Nimbus Therapeutics
2021 Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists 11021481 Nimbus Therapeutics
2021 Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists 11028085 Nimbus Therapeutics
2021 Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists 11034694 Nimbus Therapeutics
2021 Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists 11078201 Nimbus Therapeutics
2021 SHP2 phosphatase inhibitors and methods of use thereof 10934302 Relay Therapeutics
2020 Factor XIIa inhibitors 10875851 Merck & Co.
2020 Antagonists of human integrin α4β7 10759756 Morphic Therapeutic
2020 Triazole ACC inhibitors and uses thereof 10800791 Nimbus Therapeutics
2020 TYK2 inhibitors and uses thereof 10562906 Nimbus Therapeutics
2020 TYK2 inhibitors and uses thereof 10562907 Nimbus Therapeutics
2020 TYK2 inhibitors and uses thereof 10570145 Nimbus Therapeutics
2020 TYK2 inhibitors and uses thereof 10577373 Nimbus Therapeutics
2020 TYK2 inhibitors and uses thereof 10647713 Nimbus Therapeutics
2020 TYK2 inhibitors and uses thereof 10781204 Nimbus Therapeutics
2020 TYK2 inhibitors and uses thereof 10793574 Nimbus Therapeutics
2019 Therapeutic compounds and compositions 10202339 Agios
2019 Therapeutically active compounds and their methods of use 10294215 Agios
2019 Glutaminase inhibitors and method of use 10414740 Agios
2019 ACC inhibitors and uses thereof 10472374 Nimbus Therapeutics
2019 TYK2 inhibitors and uses thereof 10196390 Nimbus Therapeutics
2019 TYK2 inhibitors and uses thereof 10253046 Nimbus Therapeutics
2019 TYK2 inhibitors and uses thereof 10323036 Nimbus Therapeutics
2019 TYK2 inhibitors, uses, and methods for production thereof 10336752 Nimbus Therapeutics
2019 TYK2 inhibitors and uses thereof 10508120 Nimbus Therapeutics
2018 Therapeutically active compositions and their methods of use 9856279 Agios
2018 Glutaminase inhibitors and method of use 10011574 Agios
2018 Therapeutic compounds and compositions 10029987 Agios
2018 ACC inhibitors and uses thereof 9944655 Nimbus Therapeutics
2018 TYK2 inhibitors and uses thereof 10023571 Nimbus Therapeutics
2017 Therapeutically active compounds and their methods of use 9656999 Agios
2017 Therapeutically active compounds and their methods of use 9732062 Agios
2017 Opsin-binding ligands, compositions and methods of use 9757370 Bikam
2017 Opsin-binding ligands, compositions and methods of use 9562022 Bikam
2017 IRAK inhibitors and uses thereof 9751892 Nimbus Therapeutics
2017 IRAK inhibitors and uses thereof 9790234 Nimbus Therapeutics
2017 TYK2 inhibitors and uses thereof 9630970 Nimbus Therapeutics
2017 Inhibitors of Bruton’s tyrosine kinase 9580416 Pharmacyclics
2017 Inhibitors of bruton’s tyrosine kinase 9708326 Pharmacyclics
2016 Compounds and their methods of use 9303002 Agios
2016 Therapeutically active compositions and their methods of use 9512107 Agios
2016 Opsin-binding ligands, compositions and methods of use 9353063 Bikam
2016 Opsin-binding ligands, compositions and methods of use 9499464 Bikam
2016 Neuronal pain pathway modulators 9402826 Columbia University
2016 ACC inhibitors and uses thereof 9453026 Nimbus Therapeutics
2016 IRAK inhibitors and uses thereof 9340554 Nimbus Therapeutics
2016 IRAK inhibitors and uses thereof 9481687 Nimbus Therapeutics
2016 IRAK inhibitors and uses thereof 9518065 Nimbus Therapeutics
2016 TYK2 inhibitors and uses thereof 9340540 Nimbus Therapeutics
2016 Purinone compounds as kinase inhibitors 9469642 Pharmacyclics
2015 Therapeutic compounds and compositions 9199968 Agios
2015 ACC inhibitors and uses thereof 8969557 Nimbus Therapeutics
2015 IRAK inhibitors and uses thereof 9067948 Nimbus Therapeutics
2015 IRAK inhibitors and uses thereof 9085586 Nimbus Therapeutics
2015 IRAK inhibitors and uses thereof 9175007 Nimbus Therapeutics
2015 IRAK inhibitors and uses thereof 9212190 Nimbus Therapeutics
2014 Therapeutic compounds and compositions 8785450 Agios
2014 Therapeutic compounds and compositions 8889667 Agios
2014 Neuronal pain pathway modulators 8846742 Columbia University
2014 IRAK inhibitors and uses thereof 8703941 Nimbus Therapeutics